Genfit (NASDAQ:GNFT – Get Free Report) and Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk. Volatility and Risk Genfit has a beta of 1.08, […]
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,
Boehringer Ingelheim has paid $27.3 million upfront to Sosei Heptares to develop a small molecule agonist of GPR52 to treat the positive, negative and cognitive symptoms of schizophrenia.
Sosei ushers in new era with Nxera Pharma name change fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Sosei and PharmEnable extend neurological disease drugs hunt | Business Weekly | Technology News | Business news businessweekly.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessweekly.co.uk Daily Mail and Mail on Sunday newspapers.